An Anti-apoptotic Role of NF-κB in TNFα-induced Apoptosis in an Ameloblastoma Cell Line  by Hendarmin, Laifa et al.
Introduction
 NF-κB, one of the ubiquitously expressed tran-
scription factors, is an activator of various induc-
ible target genes that maintain the balance 
between pro- and anti-apoptotic cellular path-
ways, and also regulates other vital functions1–3. 
Furthermore, the activation of classical NF-κB, a 
heterodimer containing p50 and p65 subunits, 
provides a survival signal in the majority of cell 
types.  NF-κB exists predominantly in cytoplasm 
as an inactive form by binding to the inhibitor of 
κBα (IκBα).  However, upon activation, p50-p65 
heterodimer translocates into the nucleus through 
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Abstract : Nuclear factor-κB (NF-κB) is involved in the promotion of cell survival in a variety of 
cell types.  The present study focused on the role of NF-κB in TNFα-induced apoptosis in an 
ameloblastoma.  Immunohistochemical staining revealed p65 NF-κB protein to be expressed in 
ameloblastoma tissues.  Furthermore, immunoblotting and immunocytochemistry analyses showed 
that the stimulation of TNFα in an ameloblastoma cell line (AM-1) induced p65 NF-κB transloca-
tion from the cytoplasm to the nucleus, indicating NF-κB activation.  These ﬁndings were con-
ﬁrmed by an NF-κB luciferase reporter assay, which detected enhanced NF-κB transcription activ-
ity of AM-1 cells by TNFα stimulation.  Moreover, pretreatment with SN50, a nuclear translocation 
inhibitor, prior to TNFα stimulation, effectively inhibited TNFα-induced NF-κB activation in 
AM-1 cells.  In order to reveal the role of NF-κB activation during TNFα-induced apoptosis in 
AM-1 cells, an apoptosis assay was performed, and showed that the potential of TNFα in inducing 
apoptosis in AM-1 cells was signiﬁcantly elevated by inhibiting the NF-κB activation.  These re-
sults suggest that NF-κB plays an anti-apoptotic role in TNFα-induced apoptosis in AM-1 cells.
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phosphorylation of IκBα by IκB kinase (IKK).  In 
the nucleus, p50-p65 heterodimer binds to speciﬁc 
DNA and transactivates transcription of speciﬁc 
genes4,5.  Recent studies have demonstrated that 
the inappropriate regulation of NF-κB is closely 
associated with several diseases, such as autoim-
mune diseases and cancers6.
 Ameloblastoma, a neoplasm derived from the 
odontogenic epithelium, is usually considered to 
be benign and it also grows slowly.  However, this 
tumor has the potential for local invasion with 
destructive behavior7,8.  Very little is known about 
the molecular mechanisms that regulate its 
growth, cell differentiation, and invasion into 
bone.  To elucidate this mechanism, it would be 
useful to establish an in vitro model.  We previ-
ously reported that an immortalized ameloblas-
toma cell line, AM-1, was successfully established 
by transformation using HPV-16 DNA9.  Recent 
studies have shown that TNFα induced survival 
activity in AM-1 cells through the serine-threonine 
kinase Akt and mitogen-activated protein kinase 
(MAPK) pathways, although prolonged treatment 
with TNFα effectively induced apoptosis of AM-1 
cells.  Furthermore, the potential of TNFα
-induced apoptosis in AM-1 cells was elevated by 
inhibiting the Akt and MAPK survival path-
ways10,11.
 In various types of cells, NF-κB activation 
blocks TNFα-induced apoptosis12,13.  However, the 
role of NF-κB activation during TNFα-induced 
apoptosis is still unknown in ameloblastoma.  The 
present study shows some evidence that NF-κB 
plays an anti-apoptotic role in TNFα-induced 
apoptosis in ameloblastoma.
Materials and Methods
1. Tissue sample selection and cell culture
 Specimens were surgically obtained from 24 
patients with ameloblastoma at the Department 
of Oral and Maxillofacial Surgery, Kyushu Univer-
sity Hospital.  These tissues were ﬁxed for 24–48 
h in 4％ formaldehyde (PFA) freshly prepared 
from paraformaldehyde in phosphate buffered 
saline (PBS) at 4℃.  The tissue blocks were sliced 
and stained with hematoxylin and eosin for histo-
logical diagnosis according to the World Health 
Organization International histological typing of 
odontogenic tumors14.  Ameloblastoma tissue sec-
tions were divided into 5 follicular types, 13 plexi-
form types, 3 basal cell types, and 3 desmoplastic 
ameloblastomas.
 AM-1 cells were cultured in keratinocyte-SFM 
(GIBCO, Grand Island, New York, USA), penicil-
lin-streptomycin (GIBCO), fungizone amphotericin 
B (GIBCO) and supplemented with bovine pitu-
itary extract (Kyokuto, Tokyo, Japan).  All cells 
were maintained in a humidiﬁed atmosphere of 
5％ CO2 at 37℃.  The medium was changed on 
alternate days.
2. Immunohistochemical staining
 Ameloblastoma tissues specimens were sliced 
into 4 μm sections and then were mounted on 
3-amino-propyltriethoxy-silane coated glass slides. 
The tissue sections were de-parafﬁnized and 
treated with 0.4％ pepsin in 0.01 N HCl for 60 min 
at 37℃ for antigen retrieval.  After rinsing in 
PBS, the sections were incubated with 3％ hydro-
gen peroxide for 30 min to block endogenous activ-
ity.  Next, 10％ normal goat serum was applied for 
1 h to reduce non-speciﬁc antibody binding.  As a 
primary antibody, 1:50 diluted mouse monoclonal 
anti-p65 NF-κB (BD Pharmingen, San Diego, 
USA) antibody was applied overnight in a moist 
chamber at 4℃.  After incubation with primary 
antibody, tissue sections were washed in PBS and 
treated with the Universal Immuno-enzyme Poly-
mer (UIP) method using N-HistoﬁneⓇ Simple 
Stain MAX PO (M) (Nichirei Bioscience, Tokyo, 
Japan).  The peroxidase activity was visualized by 
immersing the tissue sections in diaminobenzidine 
(Nichirei), resulting in a brown reaction product. 
Finally, the tissue sections were counterstained 
with methyl green and mounted.  For a negative 
control, PBS was applied to substitute for the pri-
mary antibody.  Samples were rinsed in PBS 
between each step.
3. Immunoblotting
 To examine the effect of TNFα alone on AM-1 
cells, serum starvation was performed for 4 h 
prior to stimulation of TNFα (Calbiochem, La 
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Jolla, CA, USA) and AM-1 cells were treated with/
without SN50 (P-600, Biomol, USA).  Next, the 
cells were lysed and homogenized using a buffer 
containing 50 mM Hepes/NaOH (pH 7.2), 0.5 M 
NaCl, 5 mM EDTA, 20 mM β-mercaptoethanol, 
1％ Triton X-100, 50 mM sodium ﬂuoride, 30 mM 
sodium pyrophosphate, 2 mM sodium orthovana-
date, 1 mM p-amidinophenyl methane-sulfonyl 
ﬂuoride hydrochloride, and protease inhibitor 
cocktails (SIGMA-Aldrich, San Louis, Missouri, 
USA).
 The protein samples (15 μg) were separated 
using 10％ or 12.5％ sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a nitrocellulose membrane (Bio-Rad 
Laboratories, Richmond, CA, USA).  After block-
ing in 5％ dried milk solution, the sheets were 
incubated in 1:1000 mouse monoclonal anti-p65 
NF-κB (BD Pharmingen), 1:1000 diluted rabbit 
polyclonal anti-IκB-α (sc-371, Santa Cruz Bio-
technology, Santa Cruz, CA, USA), or 1:1000 
diluted rabbit anti-phospho-IκB-α (sc-8404, Santa 
Cruz) antibody.  The secondary antibody was 
1:2000 diluted horseradish peroxidase-conjugated 
sheep anti-mouse IgG (Amersham, Buckingham-
shire, UK) or 1:1000 diluted horseradish peroxi-
dase-conjugated donkey anti-rabbit IgG (Amer-
sham).  The bound antibodies were visualized 
using the enhanced chemiluminescent (ECL) sys-
tem (Amersham) according to the manufacturer’s 
instructions.
4. Nuclear extract
 Nuclear extracts were prepared according to the 
nuclear extraction kit protocol (Chemicon Interna-
tional, California, USA) as previously described15. 
Brieﬂy, the cell pellet of 1 × 107 AM-1 cells was 
combined with ice-cold cytoplasmic lysis buffer 
containing 0.5 mM dithiothreitol (DTT) and 
1:1000 dilution of protease inhibitor cocktail. 
Using a syringe with a 27-gauge needle, the cell 
suspension was disrupted, followed by centrifuga-
tion at 7000 rpm at 4℃ for 20 min.  The superna-
tant was collected as the cytosol fraction.  The 
remaining pellet was resuspended in ice-cold 
nuclear extraction buffer containing 0.5 mM DTT 
and 1:1000 dilution of protease inhibitor cocktail, 
disrupted with a syringe, and agitated in a low 
speed rotator at 4℃ for 60 min.  After a ﬁnal cen-
trifugation of the cell suspension for 5 min at 
10000 rpm, the supernatant was used as the 
nuclear extract.
5. Immunocytochemical staining
 AM-1 cells were seeded onto chamber slides, 
stimulated, and ﬁxed with 4％ PFA for 15 min. 
After being rinsed in PBS, the ﬁxed AM-1 cells 
were treated with 0.1％ Triton X-100 for 10 min. 
The samples were incubated in PBS containing 
0.1％ bovine serum albumin (BSA) and 0.1％ 
Tween-20 for 30 min to block nonspeciﬁc binding. 
Diluted anti-p65 NF-κB (1:100; BD Pharmingen) 
was applied as the ﬁrst antibody and 1:100 diluted 
TRITC-Goat Anti-Mouse Ig-G (H＋ L) conjugate 
(Zymed Laboratories, San Francisco, CA, USA) 
was applied as the secondary antibody.  The slides 
were then covered with cover slips and observed 
under a ﬂuorescence microscope.  After each step, 
the samples were rinsed in PBS.
6. NF-κB-luciferase-reporter assay
 AM-1 cells cultured in a 6-well-dish were tran-
siently co-transfected with 0.5 μg NF-κB 
luciferase reporter vector or empty control vector 
(LR0051, Panomics, Freemont, CA, USA) using 
FuGene 6 (Roche, Indianapolis, USA), and with 
0.2 μg β-galactosidase control plasmid as an 
internal transfection efﬁciency standard and incu-
bated overnight.  A luciferase assay was performed 
using the luciferase assay system (Promega, Madi-
son, WI, USA).  Brieﬂy, after washing with PBS, 
40 μl of cell culture lysis buffer was added to the 
cells.  The culture dish was rocked several times, 
scraped, and then the contents were transferred to 
the micro-centrifuge tube.  The tube was vortexed 
for 15 seconds and centrifuged at 14000 rpm for 
10 min.  The resulting supernatant was collected 
and added to a luminometer tube containing 
luciferase assay reagent.  The tube was then read 
for 10 s to measure luciferase activity using a 
Lumat LB5907 Luminometer (EG ＆ Berthold 
Technology, Wildbad, Germany).  The luciferase 
activity was normalized with the β-galactosidase 
activity.
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7. Apoptosis assay
 Apoptosis assay was carried out using an 
Annexin V-ﬂuorescein isothiocyanate (FITC) apop-
tosis detection kit (APO-AF, Sigma).  Annexin V 
can identify the externalization of phosphatidyl-
serine during the early stage of apoptosis, whereas 
propidium iodide (PI) stains DNA of cells during 
the late stage of apoptosis16.  Brieﬂy, AM-1 cells 
were washed twice with ice-cold PBS and then 
resuspended in 250 μl of binding buffer (100 mM 
HEPES/NaOH, 1.4 M NaCl and 25 M CaCl2, pH 
7.5) containing Annexin V-FITC conjugate and PI 
solution.  Cell suspensions were placed at room 
temperature for 10 min before ﬂow cytometric 
analysis.  The ﬂuorescence of individual nuclei 
was measured using a FACScalibur (Becton Dick-
inson, Franklin Lakes, NJ).  Fifteen thousand 
events were acquired for each data point.
Results
1.  Expression of p65 NF-κB proteins was 
detected in ameloblastoma tissues
 Twenty of 24 ameloblastoma tissues (83.3％) 
were stained by anti-p65 NF-κB antibody with 
various immunoreactivities.  Positive staining was 
observed in the cytoplasm and nuclei of tumor 
cells (Fig. 1).  In the follicular and basal cell types, 
the expression of p65 NF-κB was stronger in the 
outer layer of the epithelial component than that 
in the inner stellate reticulum-like cells.
2.  TNFα induced the nuclear translocation 
of p65 NF-κB in AM-1 cells
 Treatment with 100 ng/ml TNFα for 10 min in 
AM-1 cells markedly increased the amount of p65 
NF-κB proteins in the nucleus, then slightly 
decreased until 60 min (Fig. 2A).  Conversely, in 
the cytoplasmic extracts, the amount of p65 NF-κ
B proteins decreased from 10 min and then 
slightly increased up to 60 min after TNFα stimu-
lation (Fig. 2B).  These results strongly suggest 
that TNFα stimulation induced the translocation 
of p65 NF-κB from the cytoplasm to the nucleus 
in AM-1 cells.
 To conﬁrm these results, immunocytochemical 
analysis was performed to examine the localiza-
tion of p65 NF-κB in AM-1 cells.  As shown in Fig-
ure 2C, the expression of p65 NF-κB was detected 
intensely in cytoplasm of untreated AM-1 cells, 
but very weakly in the nuclei.  However, p65 NF-
κB proteins were strongly expressed in the nuclei 
of AM-1 cells with TNFα stimulation.
 The cell-permeable SN50 peptide carrying a 
functional domain, nuclear localization sequence 
(NLS), can inhibit nuclear translocation of NF-κ
B/Rel complexes in the intact cells17.  In the pres-
ent study, we used 100 μg/ml SN50 that has no 
effect on the apoptosis of AM-1 cells.  The immu-
noblotting and immunocytochemical analyses 
showed that the pretreatment of AM-1 cells with 
SN50 prior to TNFα stimulation effectively inhib-
ited TNFα-induced translocation of p65 NF-κB 
(Fig. 2).
3.  TNFα induced the phosphorylation of 
IκB-α in AM-1 cells
 An immunoblotting analysis was performed to 
determine whether IκBα is phosphorylated by 
TNFα stimulation during the process of p65 NF- 
κB translocation.  Phosphorylated-IκBα (p-IκBα) 
was increased by 100 ng/ml TNFα stimulation in 
10 min, and then gradually decreased until 60 
min.  Meanwhile, the amount of IκBα was 
decreased after 10 min and gradually recovered 
up to 60 min (Fig.  3).
4.  NF-κB transcriptional activity was 
enhanced by TNFα stimulation in AM-1 
cells
 An NF-κB-luciferase-reporter assay was per-
formed in AM-1 cells in order to measure the NF-
κB transcriptional activity by TNFα stimulation. 
The stimulation by TNFα signiﬁcantly enhanced 
the transcriptional activity of NF-κB in AM-1 
cells (p ＜ 0.01).  Meanwhile, the pretreatment of 
SN50 prior to the TNFα stimulation extensively 
inhibited TNFα-induced transcriptional activity 
of NF-κB in AM-1 cells (p ＜ 0.01 ; Fig.  4).
5.  SN50 elevated the potential of TNF in 
inducing apoptosis in AM-1 cells
 To examine whether apoptotic cells were 
affected by blocking the NF-κB signaling path-
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way, an apoptosis assay was performed in AM-1 
cells by using FACScalibur17.  As shown in Figure 
5, treatment with TNFα signiﬁcantly increased 
the number of apoptotic cells with Annexin V and 
PI positive.  Furthermore, by applying SN50 prior 
to the TNFα stimulation, the number of apoptotic 
cells was extensively increased, with 19.3％ addi-
tional cells in comparison to the treatment with 
TNFα alone.
Discussion
 NF-κB exerts its anti-apoptotic effects in a wide 
variety of cells to protect them from various apop-
totic agents.  This transcription factor promotes 
Fig. 1 The expression of p65 NF-κB in ameloblastoma tissues. Ameloblastoma tissues were immu-
nohistochemically stained with anti-p65 NFκB antibody (A-C). (A) Follicular ameloblastoma, 
(B) plexiform ameloblastoma, and (C) basal cell ameloblastoma.
Fig. 2 TNFα induced p65 NF-κB translocation in AM-1 cells. AM-1 cells were starved for 12 
h, treated with/without 100 μg/ml SN50 for 1 h and stimulated with 100 ng/ml TNFα 
for 10, 30, and 60 min. The nucleus and the cytoplasm of the cell extracts were sepa-
rated and analyzed using an immunoblotting assay. (A) Nuclear extracts and (B) cyto-
plasm of TNFα-induced p65 NF-κB translocation in AM-1 cells. (C) Immunocytochem-
ical analysis of TNFα-induced p65 NF-κB translocation in AM-1 cells. AM-1 cells were 
starved for 12 h, treated with/without 50 μg/ml SN50 for 1 h and stimulated with 100 
ng/ml TNFα for 10 min. Next, the cells were stained with anti-p65 NF-κB antibody.
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cell survival through the expression of genes 
encoding anti-apoptotic proteins which directly 
block caspase activation, such as survivin and X 
chromosome-linked inhibitor of apoptosis protein 
(XIAP), members of IAP family proteins, or some 
acting at the mitochondrial level, like bcl-2 family 
proteins18.  Furthermore, NF-κB can directly acti-
vate pro-oncogenes such as cyclin D1 and c-Myc, 
and also has been implicated in the development 
or progression of human tumors19,20.  A previous 
study showed that two members of bcl-2 family 
proteins, bcl-2 and bcl-X, were observed more pre-
dominantly in the outer layer cells than in inner 
layer cells of an ameloblastoma21,22.  Similar pat-
terns were also reported for the expression of sur-
vivin in ameloblastoma23.  Consistent with these 
studies, p65 NF-κB reactivity was much higher in 
the outer layer cells than in inner layer cells of 
ameloblastoma specimens in the current study. 
These results suggest that the outer layer cells of 
Fig. 3 TNFα induced the phosphorylation of IκB in AM-1 
cells. AM-1 cells were starved for 12 h and stimulated 
with 100 ng/ml TNFα for 10, 30, and 60 min. Cell ex-
tracts were analyzed by immunoblotting assay using 
anti-IκB or anti-phospho-IκB antibody.
Fig. 4 TNFα elevated NF-κB transcriptional activity in 
AM-1 cells. AM-1 cells were transiently transfect-
ed as described in Materials and Methods, treated 
with/without 100 μg/ml SN50 for 3 h, and stimu-
lated with 100 ng/ml TNFα for 6 h. Values are the 
mean of three different experiments (＊p ＜ 0.05,  
＊＊p ＜ 0.01).
Fig. 5 SN50 signiﬁcantly elevated the potential of TNFα 
in inducing apoptosis in AM-1 cells. AM-1 cells 
were treated with/without 100 μg/ml SN50 for 3 
h before stimulation with 100 ng/ml TNFα for 24 
h. The cells were then incubated with FITC-conju-
gated Annexin V and PI solution and analyzed by 
ﬂow cytometry as described in Materials and 
Methods. Values are the mean of three different 
experiments (＊p ＜ 0.05, ＊＊p ＜ 0.01).
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ameloblastoma have higher anti-apoptotic activi-
ties in comparison to the inner layer cells.  More-
over, these members of the bcl-2 and IAP families 
might be involved in mediating the anti-apoptotic 
effects of NF-κB in ameloblastoma.
 Many types of tumors show the constitutive 
activation of NF-κB to enable tumor cells to 
escape apoptosis and to acquire drug resis-
tance24–26.  This constitutive activation of NF-κB 
can be caused by the following mechanisms: 
genetic alterations affecting the genes encoding 
NF-κB and IκB, constitutive activation of IKK 
that leads to acceleration of IκB phosphorylation, 
or mutations inactivating IκBs24.  However, in the 
present study, p65 NF-κB proteins were detected 
in the nuclear extract and p-IκBα were detected 
in the cytoplasmic extract of untreated AM-1 cells 
(Fig. 2-A, B).  Furthermore, the expression of p65 
NF-κB was not only observed in the cytoplasm, 
but also slightly in the nucleus of untreated AM-1 
cells by immunocytochemical analysis (Fig.  2-C). 
These ﬁndings suggest that the constitutive acti-
vation of NF-κB might occur in AM-1 cells.  Fur-
ther study is needed to reveal this mechanism.
 Treatment with TNFα induced the phosphory-
lation of Akt and MAPK in AM-1 cells, which 
might be involved in survival and/or proliferation 
of ameloblastoma10.  However, when the treatment 
with TNFα was prolonged until 24 h, apoptosis 
was induced in AM-1 cells11.  The present study 
showed that treatment with TNFα induced NF-κ
B activation in AM-1 cells.  Furthermore, SN50 
inhibited TNFα-induced NF-κB activation.  To 
understand the role of NF-κB in TNFα-induced 
apoptosis in AM-1 cells, an apoptosis assay was 
performed and revealed that the potential of 
TNFα in inducing apoptosis in AM-1 cells was sig-
niﬁcantly elevated by inhibiting the NF-κB acti-
vation.  These results are direct evidence that NF-
κB plays an anti-apoptotic role in TNFα-induced 
apoptosis in AM-1 cells.  Therefore, given the 
established anti-apoptotic role of NF-κB in TNF-
induced apoptosis in AM-1 cells, the inhibition of 
NF-κB activation might be a promising strategy 
to enhance the apoptotic effect of TNFα in amelo-
blastoma.
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